Cell Therapy for
MacrophOx was launched late in 2018 by Prof. Len Seymour, Dr. Phil Jakeman and Dr Kerry Fisher out of the University of Oxford’s Department of Oncology. The Founders share a vision that their innovative technologies can lead to a sea-change in the ability of gene-modified cell therapies to treat common epithelial cancers that currently account for over 70% of cancer deaths.
MacrophOx is pioneering sophisticated genetic, immunological and cell biological solutions to the major challenges that currently limit cell therapy for cancer, and is aiming to have developed its lead clinical product by the end of 2020.
The company is currently headquartered in the Innovation Building on the University of Oxford Old Road Campus. This site houses some of the most exciting start-ups in Medical Science in a new, purpose-designed building, juxtaposed to the world class oncology and genetic science of the University, which is concentrated on the Old Road campus.
MacrophOx is looking to appoint cell therapy scientists to join the laboratory research team. These individuals would be engaged in preclinical design, development and testing of our therapeutics; developing assays to show the efficacy of our cell therapy products in the context of basic and clinical research work packages. The positions are ideal for highly-motivated persons looking to join a rapidly growing company, who would enjoy the fast-paced, highly varied nature of a scientific start-up company.
MacrophOx is looking to appoint molecular scientists to join the laboratory research team. These individuals will be engaged in molecular and cellular engineering of our therapeutics, including assessment of activities and mechanism of action. The positions are ideal for highly-motivated individuals looking to join a rapidly growing company, who would enjoy the fast-paced, highly varied nature of a scientific start-up company.